Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 1Rare Diseases 1Neuroblastoma 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Genetic Predisposition to Disease 1Breast Neoplasms 1

Interventions

Metformin 2Leuprolide 2Collagenases 2Clomiphene 2tremelimumab 1durvalumab 1Temozolomide 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Propofol 1Prednisone 1Plasma Exchange 1Nivolumab 1Midazolam 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Infliximab 1Immunoglobulins 1High-Throughput Nucleotide Sequencing 1Fentanyl 1FANG vaccine 1Cyclophosphamide 1Clomipramine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rare Diseases × High-Throughput Nucleotide Sequencing × Clear all
NCT06060184 2023-09-29

IonGER

University Hospital Tuebingen

Phase NA Not yet recruiting
500 enrolled

Genetic Predisposition to Disease, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡